Xceed Molecular, a Wellesley, Mass.-based company with molecular diagnostics ambitions, is narrowing down its areas of diagnostic interest and laying the foundation for a 510(k) submission to the US Food and Drug Administration next year, according to a company official.

CEO David Deems told BioArray News last week that Xceed has "honed in on several diagnostic areas," including breast cancer and colon cancer, and is currently involved in developing assays that will eventually be used by clinicians.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Sometimes genetic tests give inconclusive results and provide little reassurance to patients, the Associated Press reports.

Vox wonders whether gene-editing crops will be viewed similarly as genetically modified organisms of if people will give them a try.

In Science this week: research regulation and reporting requirement reform, and more.

With H3Africa, Charles Rotimi has been working to bolster the representation of African participants and African researchers in genomics, Newsweek reports.